Please assess the completion status of the following clinical trial:

Trial Title: Adagloxad Simolenin/OBI-821 in Combination With TACE Therapy in HCC Patients With GALNT14-rs9679162-non-TT Genotype

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Confirmed Diagnosis of HCC~2. Has a Globo-H or SSEA-3 positive tumor as determined by IHC~3. Never received TACE/ chemotherapy/ radiotherapy or targeted agents prior to this study.~4. Patients should be in BCLC clinical stage B (multinodular asymptomatic tumors without extra-hepatic spread or portal vein invasion) with or without unilateral secondary or tertiary branches of portal vein invasion.~5. Child-Pugh functional class A or B.~6. GALNT14- rs9679162 non TT genotype~7. At least 1 measurable lesion must be present.~8. ECOG performance status 0 to 1.~9. Age \> 20 years~10. Both men and women enrolled in this trial must use adequate birth control measures during the course of the trial and 4 weeks after last treatment~11. Informed consent must be obtained prior to perform any study procedure.~12. Total bilirubin \< 3.0 mg/dL with no evidence of biliary tract obstruction.~13. Appropriate Serum alanine aminotransferase, aspartate aminotransferase, Absolute neutrophil count, Platelets and Serum creatinine~(16) Antiviral treatment for hepatitis B or C is allowed except for interferon.~Exclusion Criteria:~1. BCLC stage A.~2. Presence of extrahepatic metastasis or main portal vein thrombosis.~3. Child-Pugh score = C.~4. Significant cardiac disease as determined by investigator.~5. Serious bacterial infection requiring systemic antibiotics.~6. Pregnancy~7. Expected non-compliance.~8. Uncontrolled illness including, but not limited to, ongoing infection, congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness.~9. Bleeding esophageal or gastric varices within three months without ligation or sclerosis injection therapy.~10. Subjects with known HIV infection.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TACE alone arm (Type: ACTIVE_COMPARATOR): TACE (Transarterial Chemoembolization)
- adagloxad simolenin arm (Type: EXPERIMENTAL): TACE plus adagloxad simolenin/OBI-821 adjuvant therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).